The robust efficacy and durability data, combined with a clean safety profile, de-risk bempikibart's path to registrational trials. Watch for regulatory feedback in H2 2026 and initiation of the registration-directed program in H1 2027, which are the next key catalysts. The off-drug durability data supports a potential less-frequent maintenance dosing regimen, a key differentiator versus JAK inhibitors.
Price Chart
Executive Summary
Q32 Bio presented positive Phase 2a SIGNAL-AA Part B results for bempikibart in alopecia areata at EADV 2026, showing clinically meaningful efficacy at Week 36 and robust durability through a 16-week off-drug period. The company plans to advance bempikibart into a registration-directed program in the first half of 2027, subject to regulatory discussions. No financial data was disclosed in this filing.
Key Facts
- Mean percent reduction in SALT score from baseline of 35.3% in the mITT analysis at Week 36.
- 40.0% (10/25) of patients in the mITT analysis achieved a SALT-20 response at Week 36.
- At the 16-week off-drug time point, 44% of patients achieved a SALT-20 response, 61% achieved SALT30, and 50% achieved SALT50.
- Maintenance of response was observed in 100% of patients who entered the off-drug follow-up period, with deepening of response in 42%.
- No serious adverse events or Grade 3 or higher treatment-related adverse events were reported.
- Company plans to advance bempikibart into a registration-directed program for severe or very severe AA in the first half of 2027.
- Data from the Part B open-label extension is anticipated in the second half of 2027.
Financial Impact
No financial figures were disclosed in this filing. The positive clinical data supports the advancement of bempikibart into registrational trials, which could increase the probability of future revenue but also implies higher R&D costs.
Risk Factors
- Open-label Phase 2a design with small sample size (33 patients) limits statistical power and may not predict Phase 3 results.
- Registration-directed program requires additional capital; the filing notes the company may need additional funding to complete clinical studies.
- Competition from approved JAK inhibitors (e.g., Olumiant, Litfulo) with established market presence.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-408435 |
| Document: d13352dex991.htm | 0001193125-26-408435 |
| Document: 0001193125-26-408435-index-headers.html | 0001193125-26-408435 |
| Document: 0001193125-26-408435-index.html | 0001193125-26-408435 |
| Document: 0001193125-26-408435.txt | 0001193125-26-408435 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | SC 13G | $8.74 $7.79 | ▼ −10.87% | ▼ −9.38% | $8.71 (−0.34%) |
Sep 30, 2026 27d ago | 8-K | $8.27 $7.99 | ▼ −3.39% | ▼ −5.30% | $8.71 (+5.32%) |
Sep 14, 2026 6w ago | 8-K | $10.91 $10.47 | ▼ −4.03% | ▼ −4.14% | $8.71 (−20.16%) |
Aug 27, 2026 8w ago | Insider Cluster | $15.03 $11.99 | ▼ −20.23% | ▼ −20.34% | $8.71 (−42.05%) |
Aug 5, 2026 11w ago | 8-K | $16.49 $15.37 | ▼ −6.79% | ▼ −7.14% | $8.71 (−47.18%) |
Jul 14, 2026 14w ago | Press Release | $15.70 $15.08 | ▲ +3.95% | ▲ +2.97% | $8.71 (+44.52%) |
Jul 14, 2026 15w ago | EFFECT | $18.46 $15.04 | ▼ −18.53% | ▼ −17.23% | $8.71 (−52.82%) |
Jul 13, 2026 15w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.71 (−59.26%) |
Jul 13, 2026 15w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.71 (−59.26%) |
Jun 25, 2026 17w ago | S-3 | $13.17 $13.09 | ▼ −0.61% | ▼ −2.77% | $8.71 (−33.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers